Gonadotropin-releasing hormone agonists administration in polycystic ovary syndrome. Effects on bone mass

G. Lupoli, C. Di Carlo, V. Nuzzo, G. Vitale, D. Russo, S. Palomba, C. Nappi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Women with amenorrhea and polycystic ovaries (PCO) seem to present a relative degree of protection against bone loss caused by hypoestrogenism. We treated 20 patients affected by polycystic ovary syndrome (PCOS) with a gonadotropin-releasing hormone agonist (GnRH-a) for 6 months. After treatment mean bone mineral density (BMD) significantly decreased. We concluded that patients with PCOS have to be considered at risk of developing osteopenia when treated with GnRH-a. The relative protection against osteoporosis, that is present in amenorrheic patients with PCO, might be attributed to the characteristics of amenorrhea in these patients.

Original languageEnglish
Pages (from-to)493-496
Number of pages4
JournalJournal of Endocrinological Investigation
Volume20
Issue number8
Publication statusPublished - Sep 1997

Fingerprint

Polycystic Ovary Syndrome
Gonadotropin-Releasing Hormone
Bone and Bones
Amenorrhea
Ovary
Metabolic Bone Diseases
Bone Density
Osteoporosis
Therapeutics

Keywords

  • Bone mineral density
  • Gonadotropin-releasing hormone agonists
  • Osteopenia
  • Osteoporosis
  • Polycystic ovary syndrome

ASJC Scopus subject areas

  • Endocrinology

Cite this

Gonadotropin-releasing hormone agonists administration in polycystic ovary syndrome. Effects on bone mass. / Lupoli, G.; Di Carlo, C.; Nuzzo, V.; Vitale, G.; Russo, D.; Palomba, S.; Nappi, C.

In: Journal of Endocrinological Investigation, Vol. 20, No. 8, 09.1997, p. 493-496.

Research output: Contribution to journalArticle

Lupoli, G, Di Carlo, C, Nuzzo, V, Vitale, G, Russo, D, Palomba, S & Nappi, C 1997, 'Gonadotropin-releasing hormone agonists administration in polycystic ovary syndrome. Effects on bone mass', Journal of Endocrinological Investigation, vol. 20, no. 8, pp. 493-496.
Lupoli, G. ; Di Carlo, C. ; Nuzzo, V. ; Vitale, G. ; Russo, D. ; Palomba, S. ; Nappi, C. / Gonadotropin-releasing hormone agonists administration in polycystic ovary syndrome. Effects on bone mass. In: Journal of Endocrinological Investigation. 1997 ; Vol. 20, No. 8. pp. 493-496.
@article{8ed1e08f4d804db6b4bec7edf1534747,
title = "Gonadotropin-releasing hormone agonists administration in polycystic ovary syndrome. Effects on bone mass",
abstract = "Women with amenorrhea and polycystic ovaries (PCO) seem to present a relative degree of protection against bone loss caused by hypoestrogenism. We treated 20 patients affected by polycystic ovary syndrome (PCOS) with a gonadotropin-releasing hormone agonist (GnRH-a) for 6 months. After treatment mean bone mineral density (BMD) significantly decreased. We concluded that patients with PCOS have to be considered at risk of developing osteopenia when treated with GnRH-a. The relative protection against osteoporosis, that is present in amenorrheic patients with PCO, might be attributed to the characteristics of amenorrhea in these patients.",
keywords = "Bone mineral density, Gonadotropin-releasing hormone agonists, Osteopenia, Osteoporosis, Polycystic ovary syndrome",
author = "G. Lupoli and {Di Carlo}, C. and V. Nuzzo and G. Vitale and D. Russo and S. Palomba and C. Nappi",
year = "1997",
month = "9",
language = "English",
volume = "20",
pages = "493--496",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "8",

}

TY - JOUR

T1 - Gonadotropin-releasing hormone agonists administration in polycystic ovary syndrome. Effects on bone mass

AU - Lupoli, G.

AU - Di Carlo, C.

AU - Nuzzo, V.

AU - Vitale, G.

AU - Russo, D.

AU - Palomba, S.

AU - Nappi, C.

PY - 1997/9

Y1 - 1997/9

N2 - Women with amenorrhea and polycystic ovaries (PCO) seem to present a relative degree of protection against bone loss caused by hypoestrogenism. We treated 20 patients affected by polycystic ovary syndrome (PCOS) with a gonadotropin-releasing hormone agonist (GnRH-a) for 6 months. After treatment mean bone mineral density (BMD) significantly decreased. We concluded that patients with PCOS have to be considered at risk of developing osteopenia when treated with GnRH-a. The relative protection against osteoporosis, that is present in amenorrheic patients with PCO, might be attributed to the characteristics of amenorrhea in these patients.

AB - Women with amenorrhea and polycystic ovaries (PCO) seem to present a relative degree of protection against bone loss caused by hypoestrogenism. We treated 20 patients affected by polycystic ovary syndrome (PCOS) with a gonadotropin-releasing hormone agonist (GnRH-a) for 6 months. After treatment mean bone mineral density (BMD) significantly decreased. We concluded that patients with PCOS have to be considered at risk of developing osteopenia when treated with GnRH-a. The relative protection against osteoporosis, that is present in amenorrheic patients with PCO, might be attributed to the characteristics of amenorrhea in these patients.

KW - Bone mineral density

KW - Gonadotropin-releasing hormone agonists

KW - Osteopenia

KW - Osteoporosis

KW - Polycystic ovary syndrome

UR - http://www.scopus.com/inward/record.url?scp=0030730791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030730791&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 493

EP - 496

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 8

ER -